Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Estrella Immunopharma Inc. (ESLAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ESLAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.86% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.09 | 52 Weeks Range 0.03 - 0.19 | Updated Date 02/26/2025 |
52 Weeks Range 0.03 - 0.19 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -174.75% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9097054 |
Shares Outstanding - | Shares Floating 9097054 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Estrella Immunopharma Inc.
Company Overview
History and Background
There is no publicly known company called 'Estrella Immunopharma Inc.' listed on US stock exchanges. Therefore, providing its history, milestones, and evolution is not possible.
Core Business Areas
Leadership and Structure
Information on the leadership team and organizational structure cannot be provided as no such company exists.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
Cannot provide industry overview without a defined company and its operational sector.
Positioning
Cannot provide company positioning without a defined company.
Total Addressable Market (TAM)
Cannot provide the TAM since the company doesn't exist.
Upturn SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Competitors and Market Share
Key Competitors
Competitive Landscape
Cannot evaluate competitive advantages or disadvantages as the company doesn't exist.
Growth Trajectory and Initiatives
Historical Growth: Cannot provide historical growth data as the company doesn't exist.
Future Projections: Cannot provide future projections as the company doesn't exist.
Recent Initiatives: Cannot highlight recent strategic initiatives as the company doesn't exist.
Summary
Based on available information, no company called Estrella Immunopharma Inc. exists. Therefore, no assessment of its strength, weaknesses, or outlook can be made. It's essential to verify the accuracy of the company name and its stock symbol.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available stock market data, company directories, and financial news sources were searched, but no information for 'Estrella Immunopharma Inc.' was found.
Disclaimers:
The information provided is based on the absence of data for the specified company. This analysis assumes the company either doesn't exist, is not publicly traded, or has limited public information available. The analysis is for informational purposes only and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Estrella Immunopharma Inc.
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2021-09-14 | CEO, President & Director Dr. Cheng Liu Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.estrellabio.com |
Full time employees - | Website https://www.estrellabio.com | ||
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.